Navigation Links
F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Date:9/15/2008

Patch Provides Five Days of Continuous Control for Highly Feared Side

Effect of Chemotherapy

Expert Urges "Zero Tolerance" to Avoid Missed Treatments

BEDMINSTER, N.J., Sept. 15 /PRNewswire-FirstCall/ -- ProStrakan Group plc (LSE: PSK) today announced the U.S. Food and Drug Administration (F.D.A) approval of SANCUSO(R) (Granisetron Transdermal System), the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen.

Chemotherapy-induced nausea and vomiting (CINV) are commonly cited by patients undergoing chemotherapy as highly feared side effects. In addition to its social and emotional effects, if left untreated, CINV can lead to dehydration, malnutrition, treatment delay, or even discontinuation of treatment.

"We've made significant progress in our understanding of chemotherapy and how to prevent its side effects, yet undergoing chemotherapy remains a challenging experience on many levels," said Barbara Rogers, CRNP, MN, AOCN, Adult Hematology-Oncology Nurse Practitioner, Fox Chase Cancer Center. "We should have zero tolerance for CINV. A patch that can be applied before treatment, releasing medication consistently into the bloodstream over a number of days, has the potential to impact patient comfort and quality of life."

Despite advances in treatment, CINV remains a significant issue. Some patients expect to endure unpleasant symptoms in order to continue chemotherapy and may suffer at home while not under the supervision of a health-care professional. With one application of Sancuso, patients receive up to five consecutive days of CINV treatment.

"When my doctor told me I would need chemotherapy, my first reaction was to wonder how the treatment would affect my life," said Melvin Hren, a participant in the Sancuso clinical trial, whose tumour originated from his
'/>"/>

SOURCE ProStrakan Group plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves First Hepatitis B Viral Load Test
2. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
3. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
4. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
5. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
6. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
9. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
10. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
11. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
(Date:7/24/2014)... 24, 2014  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2014 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, July 31, 2014 ... business developments. Interested parties may access the ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , June 28 Preliminary results of ... and hypertension demonstrated that the investigational triple combination therapy ... resulted in a statistically significant greater Least Squares (LS) ... 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P ...
... Tolerx, Inc., a biopharmaceutical company developing novel ... T cell activity, today announced the initiation of a ... in autoimmune new-onset type 1 diabetes. The confirmatory Phase ... For Early or New-Onset Type 1 Diabetes) and immediately ...
Cached Medicine Technology:New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 2New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 3New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 4New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 5New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 6New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 7Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 2Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 3Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 4
(Date:7/25/2014)... Angeles, CA (PRWEB) July 25, 2014 In ... talk about, and eager to reverse the symptoms associated with ... in the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. ... a 38-year-old father from Seattle who found himself beginning to ...
(Date:7/25/2014)... 2014 A federal judge has denied ... DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected ... to go before a jury on September 1, 2014, ... July 18th, U.S. District Judge Ed Kinkeade of the ... claims may proceed to trial against Johnson & Johnson, ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Ticket ... across the board for the Guinness International Champions Cup ... Olympiacos FC at Soldier Field on Sunday, July ... their customer appreciation promo/coupon/offer code SOCCER-2014 for added savings. ... year for diehard soccer fans in North America. Countless ...
(Date:7/25/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... Heather M. Young, PhD, RN, FAAN, of the ... of the Doris Schwartz Gerontological Nursing Research Award. ... Sciences Section, is given to a member of ... contribution to gerontological nursing research. , The award ...
(Date:7/25/2014)... Reproductive Science Center (RSC) of New ... Luzzo, Lead Physician at RSC Rhode Island, received the ... in fertility care and community outreach issued by Providence ... PBN Awards ceremony held July 24th at Salve Regina ... highly regarded, emerging leaders in their field were recognized ...
Breaking Medicine News(10 mins):Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2
... Imaging Ltd.,(the "Company") (Nasdaq: EMITF ), today announced ... the trustee for the holders of the,Series A, B ... the "Notes",respectively), that due to the signing of a ... Co., the controlling shareholder of,the Trustee, and Brightman, Almagor ...
... stopping infection , , TUESDAY, April 29 (HealthDay News) -- Most ... virus itself, but new research suggests that focusing on the ... because human cells mutate at much slower rates than does ... mutating around the drug, scientists explained. , The research is ...
... is available in German . , Leipzig. ... the Czech Republic and Poland did not so far lead ... Central Europe, there are other reasons for the presence of ... are the findings of a research project conducted by the ...
... Scientists at Johns Hopkins have outlined a new path ... and asthma based on a new understanding of the ... cavities. , Researchers say their findings, to be ... Allergy and Clinical Immunology, are the first evidence describing ...
... 29 Baptist Health System, one,of Alabama,s largest ... Group to bring together the health-improvement,needs of local ... at its four hospitals. Aegis brings nearly 20 ... services with the unique,healthcare needs of area employees., ...
... Success, NEW YORK, April 29 Flashpoint ... of the Omnicom Group,(NYSE: OMC ), was ... Medical,Advertising News at the publication,s annual Manny Awards ... by innovative thinking, powerful creative, and a,collaborative approach ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes 2Health News:Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes 3Health News:Researchers Tackle HIV From a New Angle 2Health News:Researchers Tackle HIV From a New Angle 3Health News:Shrinkage and aging are Europe-wide challenges 2Health News:Shrinkage and aging are Europe-wide challenges 3Health News:Shrinkage and aging are Europe-wide challenges 4Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 2Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 3Health News:Alabama's Baptist Health System and Aegis Health Group Partner to Address Local Employers Health-Management Concerns 2Health News:Flashpoint Medica Named Agency of Year by Medical Advertising News 2
... The Epi-K is a fully automated ... surgeons to,perform a new refractive procedure ... to,mechanically cleave the epithelium from the,Bowmans ... laser ablation.,Epi-Lasik preserves the structural integrity,of ...
... The Titan Procedure is a ... infrared light source to tighten skin ... The Titan heats the dermis to ... epidermis through continuous cooling. In addition, ...
... Confidence…real time , ... system for permanent, ... XLTEK ... IOM system. Both configurations feature ...
... Combining exceptional new ... design, XLTEKs latest innovation, ... delivers biphasic intracranial stimulation ... and 300 volts and ...
Medicine Products: